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A B S T R A C T  
Objective: To measure the synergistic effects of Aloevera and Rosiglitazone on plasma glucose, oxidative stress and 
lipid profile in Type-2 Diabetic Sprague-Dawley rats. 
Subjects and Methods: A Randomized control trail was carried out in Physiology department of Army Medical College, 
Rawalpindi. Twenty healthy rats were made diabetic according to Srinivasan model. After confirmation of type 2 
Diabetes, they were randomly segregated into two equal groups. Groups were named as diabetic control group and 
Diabetic treatment group. Control group was injected normal saline and treatment group was given 150 mg/kg body 
weight of Aloevera extract and 2.5mg/kg body weight of rosiglitazone. It was half of the effective doses which were 
calculated through pilot study. 
Results: Plasma glucose, Malondialdehyde and lipid profile were significantly reduced (p<0.000) in diabetic treatment 
group as compared to diabetic control group. 
Conclusion: A significant reduction in plasma glucose, oxidative stress and lipid profile was obtained in diabetic 
treatment group although half of the effective doses were used. It would also be help in reducing side effects associated 
with use of rosiglitazone. 
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I n t r o d u c t i o n  
 
Diabetes Mellitus (DM), the third killer of the mankind, is 
increasing with alarming rate throughout the world 
especially in developing countries.1 DM is a continuous 
source of oxidative stress to the body. Oxidative stress is 
an imbalance between production of free radical 
generation and scavenging system2. It is relevant to the 
both types of diabetes and its associated complications. 
The increased production of free fatty acid (FFAs) in 
Diabetes can directly increase reactive oxygen species  
(ROS) via lipid peroxidation reactions and mitochondrial 
production.3 Chronic hyperglycemia causes oxidative 
stress by degrading antioxidant defense system and 
oxidation of glutathione pool.4 Malondialdehyde (MDA) is 
considered as an adequate indicator of lipid peroxidation 
caused by free radicals and its level is increased in 
diabetes.5 The amount of MDA is then determined by 
thiobarbituric acid (TBARS) levels.6 To protect themselves 
against  harmful  effects  of ROS,  cells  may  reduce  the  
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formation of ROS and/or enhance ROS removal.7 
Managing Diabetes is difficult due to its chronic nature 
and number of side effects associated with drugs used for 
its treatment. Complementary and alternative medicine 
(CAM) for the treatment of diabetes mellitus is becoming 
popular. It is claimed that dietary supplements and herbal 
remedies are safer than conventional drugs. Studies have 
revealed that Aloevera is rich in polysaccrides and 
flavonoids and can be used effectively against diabetes.8 
Clinical trials have indicated that supplementation with 
antioxidant is associated with reduction in the incidence of 
chronic disease morbidity and mortality. Previous results 
revealed Aloevera as hypoglycemic and antilipidemic in 
its gel extract, which may also contribute to its antioxidant 
potential. Aloevera whole leaf has about three to five 
times more constituents than gel.9  
Rosiglitazone is a known antidiabetic drug of 
thiazolidinediones family. It works by binding to 
peroxisome proliferators activated receptor gamma 
(PPARγ), nuclear regulatory protein and regulate glucose 
and fat metabolisms by improving insulin sensitivity in 
muscles and liver. These drugs decrease plasma 
triglyceride (TG) levels but are associated with weight 
gain, an increased in low density lipoprotein (LDL)-
cholesterol levels, congestive heart failure and left 
ventricular dysfunction.10 Literature survey does not reveal 
work on antidiabetic effect of Aloevera whole leaf extract, 
used in combination with rosiglitazone. Therefore, in 
present study Aloevera whole leaf extract was used in 
combination with rosiglitazone in half of its effective dose 
to overcome the side effects associated with drug and to 
look for its synergistic effects. 
S u b j e c t s  a n d  M e t h o d s  
The Randomized control trial (RCT) was carried out at 
Physiology Department Army Medical College, 
Rawalpindi in collaboration with National Institute of 
Health (NIH) Islamabad for one year. Young Aloevera 
plant due to their high medicinal quantities was purchased 
from commercial nursery in Lahore. Plant material 
identification was carried out at Herbarium of Quaid-e-
Azam University Islamabad, by the Department of Plant 
Sciences. Accession number 46624 and voucher 
specimen number 157 was obtained. A whole leaf 
process was employed in making the Aloe juice. Leaves 
were cut into sections and were pulverized into a soup 
like structure by placing them in a grinding unit. The 
filtered juice was passed through an activated charcoal 
column, which was prepared in a central funnel, to 
remove the unwanted laxative agents, aloin and aloe 
emodin which is a byproduct of rind and latex.11 Pilot 
study was performed on a group of ten rats to find the 
effective dose of Aloe vera whole leaf extract to achieve 
normoglycemia in diabetic rats. It was found that Aloe 
vera whole leaf extract in the dose of 300 mg/kg body 
weight effectively lowered plasma glucose levels in type 2 
diabetic rats. Dose of rosiglitazone was taken from 
literature. Half their effective doses were used in our 
study.  
In RCT, Twenty Sprague Dawley rats, about 90 days old 
with average weight 220±50 grams were taken from 
National Institute of Health (NIH), Islamabad. Animal 
house facility of NIH, Islamabad was used which has a 
setup according to international standards for breeding 
and housing of experimental animals. Normal pellet diet 
(NPD) was `prepared at NIH according to the standard 
approved by the Universities Federation for Animals 
Welfare. High fat diet (HFD) was specially prepared at 
NIH according to the standard used elsewhere.12 Twenty 
animals were fed with high fat diet for 2 weeks after which 
a single intra-peritoneal injection of streptozotocin 
(available as 1-gram vial, Bioworld Pharmaceutical) in the 
dose of 35 mg/kg body weight was given.12 Their fasting 
blood glucose and MDA levels along with total lipid profile 
were measured after 72 hours to confirm type 2 Diabetes 
Mellitus (T2DM).13   
After confirmation of T2DM, twenty Sprague Dawley rats 
were randomly divided into two groups as their plasma 
glucose and TG: High density lipoprotein (HDL) ratio was 
comparable to each other. Cages were labeled as control 
group and treatment group. Now each group having 10 
rats was introduced to treatment for next 21 days. 
Diabetic control group was administered 0.1ml normal 
saline intraperitoneally (I/P) daily and diabetic treatment 
group was given half the effective dose of Aloevera 
150mg/kg and rosiglitazone 2.5mg/kg body weight I/P. 
After 21 days of treatment, overnight fasted rats were 
anesthetized and 5 ml of intra-cardiac blood was collected 
to analyze plasma glucose, MDA, Lipid profile. Analysis of 
samples was done at Centre for Research in 
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Experimental and Applied Medicine (CREAM), Army 
Medical College, Rawalpindi, Pakistan. Estimation of 
glucose was done by enzymatic colorimetric 
(TRINDER’S) method.14 TG, Total cholesterol and HDL 
were estimated simultaneously on automated chemistry 
analyzer (Vitalab Selectra E). LDL was calculated by 
using Friedewald formula and very low density lipoprotein 
(VLDL) by Triglyceride/5.15 MDA levels were estimated 
through thiobarbituric acid reactive substances (TBARS) 
assay by ELISA. Data were entered into SPSS version 
16.0. Mean and standard deviation was employed for all 
the values. Data between groups were analyzed by using 
independent sample t test. The p value <0.05 was 
considered statistically signiﬁcant.  
R e s u l t s  
At the start of study, levels of plasma glucose, MDA and 
lipid profile were comparable to each other in both groups. 
After 21 days of treatment, a marked reduction in plasma 
glucose, MDA and lipid profile was noted in treatment 
group as compared to baseline (Table 1). After treatment 
plasma glucose, serum TG, cholesterol, LDL and VLDL 
were significantly reduced in Diabetic control group as 
compared to Diabetic treatment group. Serum HDL levels 
were noted to be significantly increased in treatment 
group (Table 2). After three weeks, MDA level in the 
control group was 10.06 ± 1.07 µmol/l and in treatment 
group it was significantly (p<0.000) reduced i.e. 3.65 ± 
0.39 µmol/L  (Figure 1). 
D i s c u s s i o n  
The Srinivasan animal model of T2DM was used in this 
study because it closely resembled the natural course and 
metabolic characteristics of the disease.12 The animal 
models constructed with alloxon and streptozotozin 
resulted in extreme insulin deficiency and overt  
Table 1: Percent reduction in treatment group as 
compared to baseline (n=10) 
Variables percentage 
Blood glucose 73 
Malondialdehyde 64 
Triglyceride 50 
Total Cholesterol 46 
High density lipoprotein 25 
Low density lipoprotein 51 
Very low density lipoprotein 49 
 
Figure-1: Effect of Aloevera and rosiglitazone on MDA 
levels in type 2 diabetic treatment group as compared 
to control group (n=20) 
 
hyperglycemia features similar to type DM-1 than to DM-
2. Models. Administration of high fat diet for 2 weeks 
followed by low dose of streptozotocin resulted in frank 
hyperglycemia, hyperinsulimemia and insulin resistance. 
These findings were consistent with the published data of 
different studies.12 We used TG: HDL ratio of 1.8 as cut 
off point for presence of insulin resistance. In both groups 
after inducing T2DM it was more than 1.8. However, in a 
study by Srinivasan, hyperinsulinemia (467.50 ± 32.43 
pmol/l) was taken as the indicator of insulin resistance in 
high fat fed rats.12 Aloevera and Rosiglitazone combine 
supplementation in the present study has resulted in 
statistically significant (p<0.00001) reduction in plasma 
glucose levels when compared with Diabetic control group 
even when half of their effective doses were used. To 
latest literature, survey has revealed that no study has so 
far been conducted in which Aloevera extract and 
rosiglitazone are used in combination to treat type 2 
Diabetes Mellitus. However, our results are encouraging 
when compared with studies where these drugs are used 
alone for T2DM. 
The work of Tanka et al on Diabetic mouse strain BKS 
Cg-m Lepr (db/db) with Aloe vera gel extract resulted in 
significant (p<0.05) reduction in fasting plasma glucose 
level by 64% in diabetic mice when treated for 35 days.16 
Our study revealed 73%% reduction in plasma glucose 
level in combined group. The desired results in Tanka 
study were obtained after 35 days of treatment, while 
duration of our study was shorter (21 days) with much 
better results. This may be due to synergistic effects of 
Aloevera and rosiglitazone in combined group.  
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Table 2: After treatment comparison of Plasma glucose, MDA and Lipid profile between groups (n=20) 
Variables Diabetic control Group (n=10) 
Mean±SD 
Treatment Group (n=10) Mean±SD p value 
Plasma glucose (mmol/l) 19.05 ± 1.70 5.14 ± 0.25 <0.000 
MDA (µmol/l) 10.06 ±1.07 3.65 ± 0.39 <0.000 
Triglyceride (mmol/l) 3.96 ± 0.41 1.98 ± 0.14 <0.000 
Cholesterol (mmol/l) 4.54 ± 0.21 2.45 ± 0.13 <0.000 
HDL- cholesterol (mmol/l) 0.40 ± 0.08 0.50 ± 0.07 0.0005 
LDL- cholesterol (mmol/l) 3.26 ± 0.40 1.6± 0.22 <0.0000 
VLDL – cholesterol (mmol/l) 0.79 ± 0.07 0.4± 0.71 <0.000 
 
In our study whole leaf extract rather than only gel part of 
Aloevera. was used which may also contribute towards 
better results in short time of 21 days rather than 35 days 
taken by tanka study. In their study, they also identified 
five phytosterol but all did not show antihyperglycemic 
effects, supporting the documented observation regarding 
the synergistic action of number of constituents rather 
than one component alone.17 
In present study, oxidative stress was measured by 
estimating the levels of MDA in plasma. The 
concentration of MDA in diabetic group was 10.06 ±1.07 
µmol/l which could be due to high fat diet (HFD) and 
streptozotocin treatment which generally induces 
oxidative predominance in tissue by generating reactive 
oxygen species.18 The MDA levels decreased by 64%  in 
combined group which could be due to its antioxidant 
properties as Aloe vera has been reported to have strong 
antioxidant potential than alpha tocopherol.19 It has been 
documented that Aloevera extract normalized the 
deranged plasma glucose and lipid status and improved 
the antioxidant status, which may also contribute in 
lowering oxidative stress.20  Aloevera can contribute to its 
antioxidant status due to presence of vitamins (C, E,) 
enzymes (GPx, SOD, catalase).21  The combined group  
results can be attributed to  its synergistic action. In a 
study conducted by Can et al reported the effect of 
Aloevera leaf gel and pulp extract had reduced the MDA 
levels by 18% and 13% respectively. They attributed the 
antioxidant effect to alerosin derivative present in latex.22 
Plasma MDA levels of our study were more profound than 
Cans’ study. This may be due to the longer duration of 
treatment in our study design. Secondly, they had used 
gel and pulp of Aloevera separately while we used whole 
leaf extract. The antioxidant potency of Aloevera is  
 
already known which was attributed to the presence of 
aloe emodin present in the gel.23 However in our study we 
had removed aloe emodin and still a significant (64%) 
decrease in MDA level was observed despite half the 
effective dose of drug was used. This could be due to 
synergistic action of Aloevera and rosiglitazone when 
used in combination. 
In the present study, after  intake of HFD for three weeks 
the diabetic rats showed severe derangements in plasma 
lipid profile because intake of high fat diet was associated 
with increase in plasma triglycerides, cholesterol, LDL, 
VLDL and decrease in HDL levels, similar to previous 
studies.24 Combined group supplementation in the 
present study has resulted in statistically significant 
(p<0.00001) improvement in plasma TG, cholesterol, 
LDL, VLDL and HDL levels when compared with diabetic 
control group. Combined group reduced the levels of TG’s 
by 50%, cholesterol 46%, LDL 51%, VLDL 49% and 
increased HDL by 25% as compared to diabetic rats at 
the end study. These results were better than when 
Aloevera was used alone. No study is available, in which 
Aloevera and rosiglitazone is used in combination in half 
of their effective dose. However, Aloevera used alone 
showed antilipidemic effects. The findings are supported 
by the published data of different studies. 
A study by Kim et al revealed that processed Aloevera gel 
has significantly reduced TG and raised HDL with no 
effects on cholesterol despite 8 weeks of treatment. They 
attributed this effect to reduced lipogensis and which was 
assessed/analyzed by the decrease in adipocyte size.25 
Our study results were much better due to usage of whole 
leaf extract as well as synergistic action of two drugs 
despite their usage in half of their effective dose. A study 
on Aloe vera gel high molecular weight fractions (AHM), 
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given to fifteen patients with uncontrolled T2DM.The 
results revealed a significant reduction in TG with no 
effect on cholesterol level.26 However our study in 
combined group showed statistically significant results on 
TG, Cholestrol, VLDL and LDL while rise in HDL level. in 
combined group. This may be due to the fact that only a 
fraction from Aloevera gel was separated and used in this 
study. It has been reported that despite small solid 
contents of Aloevera, its multiple therapeutic effects of 
Aloevera are due to the synergestic effects of its 
components. Phenolic compounds and saponins are 
known to reduce hyperlipidemia in diabetes.27 The 
hypoglycemic effect of Aloevera extract may be implicated 
as the major reason for the observed antihyperlipidemic 
effect of the extract because glycemic control is the major 
determinant of total cholesterol, VLDL, and triglyceride 
levels. Aloe chrome increases insulin sensitivity by 
increasing adiponectin level. Five chromones have been 
identified in Aloe vera extract.28 Phytosterol, lophenol (Lo) 
and cycloartanol (Cy), may act as ligand for PPAR.29  
Rosiglitazone is a known antidiabetic drug of 
thiazolidinediones family. It has been used for the 
treatment of type 2 DM since 1991. It increases insulin 
sensitivity and improves glycemic control. It also acts as a 
ligand for the gamma subtype of peroxisome proliferators 
activated receptor (PPAR- gamma), which is directly 
involved in the regulation of genes controlling glucose 
homeostasis and lipid metabolism. 30 In our study the 
plasma glucose levels are reduced by 73%%, TG 50%, 
cholesterol 46%, LDL 51%, VLDL 49% with concomitant 
increase in HDL by 25% despite the fact that half of its 
effective dose were used. These findings of combined are 
similar to many clinical trials carried in the past when 
rosiglitazone were used alone. However, no study is 
available in literature for using Alevera and rosiglitazone 
in combination.  
In a study conducted by Atanasovska et al,  rosiglitazone 
treatment in a dose of 5mg/kg body weight to fructose 
induced metabolic syndrome winstar rats resulted in a 
statistically significant (<0.001) decreased in  plasma 
glucose and TG.31 They concluded that these effects may 
probably involve a regulation of the enzyme lipoprotein 
lipase in the adipose tissue.32 It has been reported in that 
a patient receiving 4mg/kg body weight of rosiglitazone 
showed signs and symptoms of hepatocellular injury. 
Discontinuation of treatment was advised to him.33 The 
volume overload is responsible for heart failure 
associated with thiazolidines rather than direct effect on 
cardiac function.34 However in our study with 2.5mg/kg 
body weight of rosiglitazone along with Aloevera in 
combination resulted in effective reduction in glucose 
lipids and MDA level. This will help in reducing the side 
effects associated with drug. 
C o n c l u s i o n  
The data of our study has revealed encouraging results 
which could help evolve new strategy of treatment for 
T2DM. The use of natural herb with synthetic drug may 
help to lessen the financial burden associated with this 
disease. In addition, the side effects associated with 
prolong use of rosiglitazone such as myocardial infarction 
and heart failure due to high LDL. It has been suggested 
that use of lipid lowering drug may reduce this risk. Our 
study has beneficial effect on normalizing the oxidative 
stress and lipid profile, in type 2 Diabetics. It demands for 
a study on human T2DM patients by using Aloevera with 
rosiglitazone in half the effective dose to explore a new 
combination of treatment. 
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